G-418

• Description:

  G-418 (Geneticin) is an aminoglycoside antibiotic with a structure similar to gentamicin. It is toxic to both eukaryotic and prokaryotic cells and works by interfering with protein synthesis[1].

• Product Name Alternative:

  Geneticin; Antibiotic G-418

• UNSPSC:

  12352005

• Hazard Statement:

  H301

• Target:

  Antibiotic; Bacterial; Parasite

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/g-418.html

• Purity:

  99.04

• Solubility:

  DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 125 mg/mL (ultrasonic)

• Smiles:

  O[C@@H]([C@@H]1O[C@@]([C@@H]([C@@H](O)[C@@H]2O)N)([H])O[C@]2([H])[C@H](O)C)[C@H]([C@@H](C[C@@H]1N)N)O[C@](OC[C@](C)(O)[C@@H]3NC)([H])[C@@H]3O

• Molecular Formula:

  C20H40N4O10

• Molecular Weight:

  496.55

• Precautions:

  H301

• References & Citations:

  [1]S Bennett, et al. Reliable method of isolating transfected clones from the LNCaP human prostatic cell line. Biotechniques. 1997 Jul;23 (1) :66, 68, 70.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Aminoglycoside

• Citation 01:

  Acta Pharmacol Sin. 2023 Oct;44 (10) :2103-2112.|Biochem Pharmacol. 2025 Sep 13;242 (Pt 2) :117337.|Biochem Pharmacol. 2026 Jan;243 (Pt 2) :117529.|Cell Biosci. 2025 Apr 13;15 (1) :46.|Cell Mol Biol Lett. 2024 Feb 17;29 (1) :26.|FASEB J. 2023 Nov;37 (11) :e23195.|Research Square Preprint. 2023 Jul 11.|SSRN. 2024 Jun 19.|Acta Pharmacol Sin. 2025 Nov 1.|Adv Healthc Mater. 2025 Apr;14 (10) :e2404501.|Adv Sci (Weinh) . 2025 Apr;12 (13) :e2404961.|Adv Sci (Weinh) . 2025 Nov 3:e13380.|Am J Cancer Res. 2021 May 15;11 (5) :2062-2080.|Biologics. 2025 Aug 12:19:443-462.|BMC Complement Med Ther. 2024 Nov 16;24 (1) :400.|Cancer Commun (Lond) . 2023 Jan;43 (1) :123-149.|Cancer Res. 2023 Apr 4;83 (7) :1048-1061.|Cell Death Differ. 2020 Jun;27 (6) :1981-1997.|Cell Death Dis. 2020 Jun 4;11 (6) :420.|Cell Death Dis. 2019 May 28;10 (6) :413.|Cell Rep. 2020 Oct 20;33 (3) :108287.|Cell Rep. 2021 Mar 30;34 (13) :108906.|Cell Rep. 2021 Sep 21;36 (12) :109739.|Cell Rep. 2022 Oct 25;41 (4) :111561.|Chemosphere. 2024 Oct:366:143350.|Drug Resist Updat. 2026 Jan:84:101319.|Emerg Microbes Infect. 2023 Dec;12 (2) :2261556.|Environ Toxicol. 2024 Sep;39 (9) :4447-4458.|Eur J Pharmacol. 2025 May 15:995:177418.|Exp Mol Med. 2025 Nov;57 (11) :2686-2698.|Hum Cell. 2022 Sep;35 (5) :1475-1486.|Int J Biol Macromol. 2025 Dec;333 (Pt 1) :148831.|Int J Biol Macromol. 2025 Sep 17;329 (Pt 1) :147753.|J Agric Food Chem. 2022 Apr 6;70 (13) :3989-3999.|J Biol Chem. 2023 May;299 (5) :104621.|J Cell Mol Med. 2023 Apr;27 (7) :962-975.|J Ethnopharmacol. 2025 Jun 2:120086.|J Genet Genomics. 2021 Feb 20;48 (2) :134-146.|Life Sci. 2024 Jun 1:346:122626.|Med Oncol. 2021 Nov 10;39 (1) :10.|Mol Cell. 2023 Dec 7;83 (23) :4370-4385.e9.|Nature. 2023 Jun;618 (7966) :862-870.|Oxid Med Cell Longev. 2022 Jan 28;2022:8168988.|Patent. US20240299557A1.|Protein Cell. 2025 Feb 18:pwaf014.|Purdue University. 2025.|Redox Biol. 2025 Aug 27:86:103847.|Research Square Preprint. 2020 Jun.|Research Square Preprint. 2021 Nov.|Research Square Print. 2023 Feb 21.|Sci Adv. 2024 Aug 16;10 (33) :eado1533.|Sci Rep. 2025 Jul 2;15 (1) :23651.|Theranostics. 2022 Jan 1;12 (3) :1187-1203.|Transl Cancer Res. 2023 Jan 30;12 (1) :150-162.|Transl Psychiatry. 2025 Apr 2;15 (1) :116.

• CAS Number:

  [49863-47-0]